

Philippe Rousselot

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8730988/publications.pdf>

Version: 2024-02-01

227
papers

22,641
citations

27035

58
h-index

9605

147
g-index

230
all docs

230
docs citations

230
times ranked

16118
citing authors

#	ARTICLE	IF	CITATIONS
1	Matchpoint: the game is not over for blast-phase chronic myeloid leukaemia. <i>Lancet Haematology</i> , 2022, 9, e86-e87.	2.2	0
2	Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. <i>Leukemia</i> , 2022, 36, 1825-1833.	3.3	43
3	Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial. <i>Leukemia</i> , 2021, 35, 2332-2345.	3.3	15
4	BiTtEn by Src inhibitors. <i>Blood</i> , 2021, 137, 867-868.	0.6	0
5	Ponatinib long-term follow-up of efficacy and safety in CP-CML patients in real world settings in France: The POST-PACE study. <i>Leukemia Research</i> , 2021, 104, 106541.	0.4	4
6	Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients. <i>British Journal of Haematology</i> , 2021, 194, 393-402.	1.2	22
7	PPAR β agonists promote the resolution of myelofibrosis in preclinical models. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	4
8	KMT2A-ARHGEF12, a therapy related fusion with poor prognosis. <i>Molecular Biology Reports</i> , 2021, 48, 7021-7027.	1.0	2
9	Early detection of <i>WT1</i> measurable residual disease identifies high-risk patients, independent of transplantation in AML. <i>Blood Advances</i> , 2021, 5, 5258-5268.	2.5	12
10	The Omission of High-Dose Cytarabine during Consolidation Therapy of Ph-Positive ALL Patients Treated with Nilotinib and Low-Intensity Chemotherapy Results in an Increased Risk of Relapses Despite Non-Inferior Levels of Late BCR-ABL1 MRD Response. First Results of the Randomized Graaph-2014 Study. <i>Blood</i> , 2021, 138, 512-512.	0.6	9
11	Post Hoc Analysis of Responses to Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) By Baseline <i>BCR-ABL1</i> Level and Baseline Mutation Status in the Optic Trial. <i>Blood</i> , 2021, 138, 307-307.	0.6	3
12	Treatment Free Survival (TFS) in Patients (pts) with Chronic Myeloid Leukemia (CML) Carrying Atypical BCR-ABL1 Fusion Transcripts: The French CML Group (Fi-LMC) Experience. <i>Blood</i> , 2021, 138, 3604-3604.	0.6	0
13	Fractionated Inotuzumab Ozogamicin Combined with Low-Intensity Chemotherapy Provides Very Good Outcome in Older Patients with Newly Diagnosed CD22+ Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia: First Results from the EWALL-INO Study. <i>Blood</i> , 2021, 138, 511-511.	0.6	10
14	Frequency and Outcome of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with BCR-ABL1 Clonal Hematopoiesis after Blast Clearance: Results from the Graaph-2014 Trial. <i>Blood</i> , 2021, 138, 3478-3478.	0.6	3
15	Dose Modification Dynamics of Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) from the PACE and Optic Trials. <i>Blood</i> , 2021, 138, 2550-2550.	0.6	8
16	Replacing the Anthracycline By Gemtuzumab Ozogamicin in Older Patients with De Novo Standard-Risk Acute Myeloid Leukemia Treated Intensively - Results of the Randomized ALFA1401-Mylofrance 4 Study. <i>Blood</i> , 2021, 138, 31-31.	0.6	4
17	Retrospective Analysis of the Outcomes of Patients with Relapsed/Refractory Acute Myeloid Leukemia Included in a Patient Named Program of Gemtuzumab Ozogamicin. <i>Blood</i> , 2021, 138, 876-876.	0.6	1
18	Frontline Consolidation with Blinatumomab for High-Risk Philadelphia-Negative Acute Lymphoblastic Adult Patients. Early Results from the Graall-2014-QUEST Phase 2. <i>Blood</i> , 2021, 138, 1232-1232.	0.6	10

#	ARTICLE	IF	CITATIONS
19	<i>Treatment-Free Remissions in Newly Diagnosed CP CML Patients Treated with the Combination of Nilotinib + Pegylated Interferon Alpha 2a Versus Nilotinib Alone in the National Phase III Petals Trial</i>. Blood, 2021, 138, 2553-2553.	0.6	3
20	Epidemiology, clinical picture and long-term outcomes of <i>FIP1L1&PDGFRA</i>-positive myeloid neoplasm with eosinophilia: Data from 151 patients. American Journal of Hematology, 2020, 95, 1314-1323.	2.0	37
21	Highlights on the risk of pulmonary tuberculosis in patients on ibrutinib treatment: Case report and literature review. EJHaem, 2020, 1, 601-603.	0.4	2
22	CML-114: Interim Analysis from the OPTIC Trial - A Dose-Ranging Study of 3 Starting Doses of Ponatinib. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S234.	0.2	3
23	Rapid screening of COVID-19 patients using white blood cell scattergrams, a study on 381 patients. British Journal of Haematology, 2020, 190, 718-722.	1.2	19
24	Late molecular recurrences in patients with chronic myeloid leukemia experiencing treatment-free remission. Blood Advances, 2020, 4, 3034-3040.	2.5	34
25	Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia. Haematologica, 2019, 104, 93-101.	1.7	62
26	Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients. Clinical Cancer Research, 2019, 25, 6606-6613.	3.2	82
27	Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome. British Journal of Haematology, 2019, 187, 337-346.	1.2	31
28	Common clonal origin of an EBV-positive diffuse large B cell lymphoma and a chronic myelomonocytic leukemia. Leukemia and Lymphoma, 2019, 60, 3327-3329.	0.6	1
29	The Combination of Nilotinib + Pegylated IFN Alpha 2a Provides Somewhat Higher Cumulative Incidence Rates of MR4.5 at M36 Versus Nilotinib Alone in Newly Diagnosed CP CML Patients. Updated Results of the Petals Phase III National Study.. Blood, 2019, 134, 494-494.	0.6	12
30	The TKI-Free Duration after a First Discontinuation Attempt That Failed in CP CML Patients Is a Predictive Factor of TKI-Free Remission after a Second Attempt. Blood, 2019, 134, 28-28.	0.6	13
31	Sensitive Monitoring of BCR-ABL1 Kinase Domain Mutations By Next Generation Sequencing for Optimizing Clinical Decisions in Philadelphia-Positive Acute Lymphoblastic Leukemia in the Graaph-2014 Trial. Blood, 2019, 134, 1295-1295.	0.6	4
32	Prognostication of Molecular Relapses after Dasatinib or Nilotinib Discontinuation in Chronic Myeloid Leukemia (CML): A FI-LMC STOP 2G-TKI Study Update. Blood, 2019, 134, 30-30.	0.6	27
33	Pregnancy Management in CML Patients: To Treat or Not to Treat? Report of 224 Outcomes of the European Leukemia Net (ELN) Database. Blood, 2019, 134, 498-498.	0.6	11
34	Mechanistic Insights into the Inhibition of T Regulatory Cells By Dasatinib May Predict Immunostimulatory Effects in CML Patients. Blood, 2019, 134, 1635-1635.	0.6	1
35	A Report on 114 Patients Who Experienced Treatment Free Remission in a Single Institution during a 15 Years Period: Long Term Follow-up, Late Molecular Relapses and Second Attempts. Blood, 2019, 134, 27-27.	0.6	6
36	The Combination of Venetoclax and Tofacitinib Induced Hematological Responses in Patients with Relapse/ Refractory T-ALL with BCL2 Expression and Surface IL7R Expression or IL7R-Pathway Mutations (On behalf of the GRAALL). Blood, 2019, 134, 1339-1339.	0.6	2

#	ARTICLE	IF	CITATIONS
37	Interim Results of the Real-Life Study Evaluating the Efficacy and Safety of Ponatinib "Topase" Reveals Induction of Early Molecular Responses in Patients with TKI-Resistant or Intolerant CML. <i>Blood</i> , 2019, 134, 5908-5908.	0.6	0
38	The rising prevalence of chronic myeloid leukemia in France. <i>Leukemia Research</i> , 2018, 69, 94-99.	0.4	21
39	DNA methylation profiling reveals a pathological signature that contributes to transcriptional defects of CD 34 + CD 15 ^{hi} cells in early chronic phase chronic myeloid leukemia. <i>Molecular Oncology</i> , 2018, 12, 814-829.	2.1	22
40	Dasatinib dose management for the treatment of chronic myeloid leukemia. <i>Cancer</i> , 2018, 124, 1660-1672.	2.0	19
41	Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group. <i>Cancer</i> , 2018, 124, 2956-2963.	2.0	63
42	Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. <i>Lancet Oncology</i> , The, 2018, 19, 747-757.	5.1	444
43	Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 1659-1665.	0.6	15
44	Management of ITK pulmonary and pleural adverse effects: Fi-LMC guidelines. <i>Hematologie</i> , 2018, 24, 134-144.	0.0	0
45	Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review. <i>Journal of Hematology and Oncology</i> , 2018, 11, 143.	6.9	52
46	Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study. <i>Experimental Hematology</i> , 2018, 67, 41-48.	0.2	34
47	Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 889-903.	5.1	205
48	Nivolumab to control molecular response in chronic myeloid leukemia. <i>Leukemia Research</i> , 2018, 72, 5-6.	0.4	2
49	Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. <i>Leukemia</i> , 2018, 32, 1768-1777.	3.3	184
50	The story of tyrosine kinase inhibitors discontinuation in clinical practice. <i>Leukemia and Lymphoma</i> , 2018, 59, 2782-2791.	0.6	2
51	Oncogenic Predictors of Outcome in Older AML Patients Treated Intensively. Analysis of the ALFA-1200 Trial. <i>Blood</i> , 2018, 132, 993-993.	0.6	2
52	Nilotinib (Tasigna®) and Low Intensity Chemotherapy for First-Line Treatment of Elderly Patients with BCR-ABL1-Positive Acute Lymphoblastic Leukemia: Final Results of a Prospective Multicenter Trial (EWALL-PH02). <i>Blood</i> , 2018, 132, 31-31.	0.6	36
53	Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study. <i>Haematologica</i> , 2017, 102, 1368-1377.	1.7	114
54	Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study. <i>Cancer</i> , 2017, 123, 1791-1799.	2.0	75

#	ARTICLE	IF	CITATIONS
55	Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. <i>Blood</i> , 2017, 129, 846-854.	0.6	268
56	Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia. <i>Cancer</i> , 2017, 123, 4403-4410.	2.0	85
57	Bone marrow mesenchymal stromal cell (MSC) gene profiling in chronic myeloid leukemia (CML) patients at diagnosis and in deep molecular response induced by tyrosine kinase inhibitors (TKIs). <i>Leukemia Research</i> , 2017, 60, 94-102.	0.4	19
58	Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2017, 35, 298-305.	0.8	380
59	A case of 8p11 syndrome associated with acute erythroblastic leukemia and T-lymphoblastic lymphoma treated with ponatinib combination and chemotherapy. <i>Hematologie</i> , 2017, 23, 135-143.	0.0	0
60	Randomized Phase 2 Trial of Lirilumab (anti-KIR monoclonal antibody, mAb) As Maintenance Treatment in Elderly Patients (pts) with Acute Myeloid Leukemia (AML): Results of the Effikir Trial. <i>Blood</i> , 2017, 130, 889-889.	0.6	25
61	Nilotinib Versus Nilotinib Combined to Pegylated-Interferon Alfa 2a in First-Line Chronic Phase Chronic Myelogenous Leukemia Patients. Interim Analysis of a Phase III Trial. <i>Blood</i> , 2017, 130, 899-899.	0.6	4
62	À%radication ou À©rosion des cellules souches leucÀ©miques: greffes hÃ©matopoÃ©tiques et nouvelles molÃ©cules. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2017, 201, 167-177.	0.0	0
63	Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosomeâ€‘positive ALL. <i>Blood</i> , 2016, 128, 774-782.	0.6	243
64	The Plasmair Decontamination System Is Protective Against Invasive Aspergillosis in Neutropenic Patients. <i>Infection Control and Hospital Epidemiology</i> , 2016, 37, 845-851.	1.0	5
65	Dasatinib in imatinibâ€™resistant or â€™intolerant chronicâ€™phase, chronic myeloid leukemia patients: 7â€™year followâ€™up of study CA180â€™034. <i>American Journal of Hematology</i> , 2016, 91, 869-874.	2.0	145
66	Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. <i>Journal of Clinical Investigation</i> , 2016, 126, 3207-3218.	3.9	208
67	The Upper Age Limit for a Pediatric-Inspired Therapy in Younger Adults with Ph-Negative Acute Lymphoblastic Leukemia (ALL)? Analysis of the Graall-2005 Study. <i>Blood</i> , 2016, 128, 762-762.	0.6	13
68	Second TKI Discontinuation in CML Patients That Failed First Discontinuation and Subsequently Regained Deep Molecular Response after TKI Re-Challenge. <i>Blood</i> , 2016, 128, 788-788.	0.6	4
69	Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation. <i>Oncotarget</i> , 2016, 7, 35293-35301.	0.8	54
70	A <scp>P</scp>hase 2 study of <scp>L</scp>â€™asparaginase encapsulated in erythrocytes in elderly patients with <scp>P</scp>hiladelphia chromosome negative acute lymphoblastic leukemia: The <scp>GRASPALL/GRAALLâ€™6A</scp>2â€™2008 study. <i>American Journal of Hematology</i> , 2015, 90, 811-818.	2.0	64
71	Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia. <i>Oncotarget</i> , 2015, 6, 22812-22821.	0.8	45
72	Genetic polymorphisms associated with increased risk of developing chronic myelogenous leukemia. <i>Oncotarget</i> , 2015, 6, 36269-36277.	0.8	27

#	ARTICLE	IF	CITATIONS
73	Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicentre, non-randomised, open-label phase 2 study. <i>Lancet Haematology</i> , 2015, 2, e37-e46.	2.2	45
74	Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. <i>Blood</i> , 2015, 125, 3711-3719.	0.6	291
75	Erosion of the chronic myeloid leukaemia stem cell pool by PPAR γ agonists. <i>Nature</i> , 2015, 525, 380-383.	13.7	237
76	Clofarabine for the treatment of adult acute lymphoid leukemia: the Group for Research on Adult Acute Lymphoblastic Leukemia intergroup. <i>Leukemia and Lymphoma</i> , 2015, 56, 847-857.	0.6	28
77	Personalized Daily Doses of Imatinib By Therapeutic Drug Monitoring Increase the Rates of Molecular Responses in Patients with Chronic Myeloid Leukemia. Final Results of the Randomized OPTIM Imatinib Study. <i>Blood</i> , 2015, 126, 133-133.	0.6	31
78	Combination of Dasatinib and Peg-Interferon Alpha 2b in Chronic Phase Chronic Myeloid Leukemia (CP-CML) First Line: Preliminary Results of a Phase II Trial, from the French Intergroup of CML (Fi-LMC). <i>Blood</i> , 2015, 126, 134-134.	0.6	10
79	Osteoarticular Pain after Discontinuation of Tyrosine Kinase Inhibitors (TKI): A French Cohort. <i>Blood</i> , 2015, 126, 137-137.	0.6	14
80	Pegylated Interferon-Alpha 2a in Combination with Nilotinib As First-Line Therapy in Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (Nilopeg trial). Four-Year Follow-up Results. <i>Blood</i> , 2015, 126, 1578-1578.	0.6	2
81	Long-Term Follow-up of the French 1 Stop Imatinib Study (STIM1) in Chronic Myeloid Leukemia Patients. <i>Blood</i> , 2015, 126, 345-345.	0.6	12
82	<i>IDH1/2</i> but not <i>DNMT3A</i> mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association. <i>Oncotarget</i> , 2015, 6, 42345-42353.	0.8	92
83	GATA2 Expression Level in Chronic Myeloid Leukemia (CML) Patients Correlates with Their Prognostic Scores and Is Associated with Disease Stage at Diagnosis. <i>Blood</i> , 2015, 126, 2768-2768.	0.6	1
84	Ponatinib for Chronic Phase (CP) CML Failing Two or More Tyrosine Kinase Inhibitors (TKI) or Harboring a T315I Mutation in the Real Life: Pearl Observational Study. <i>Blood</i> , 2015, 126, 4039-4039.	0.6	0
85	Reply to J. Richter et al. <i>Journal of Clinical Oncology</i> , 2014, 32, 2823-2825.	0.8	11
86	Complex karyotype in mantle cell lymphoma is a strong prognostic factor for the time to treatment and overall survival, independent of the MCL international prognostic index. <i>Genes Chromosomes and Cancer</i> , 2014, 53, 106-116.	1.5	57
87	Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib. <i>Blood</i> , 2014, 123, 3574-3577.	0.6	118
88	BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia. <i>Cancer Cell</i> , 2014, 26, 428-442.	7.7	292
89	Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse. <i>American Journal of Hematology</i> , 2014, 89, 399-403.	2.0	22
90	Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease. <i>Journal of Clinical Oncology</i> , 2014, 32, 424-430.	0.8	355

#	ARTICLE	IF	CITATIONS
91	Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. <i>Blood</i> , 2014, 123, 2317-2324.	0.6	167
92	Long Term Outcome of Chronic Phase Chronic Myeloid Leukemia (CP CML) Patients (pts) from the French Spirit Study Comparing Imatinib (IM) 400 Mg to Higher Dose Imatinib or Combination with Peg-interferon±2a (PegIFN) or Cytarabine (Ara-C) : A Trial of the FI LMC (France intergroupe de la Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.6	4
93	Inversely to DNMT3A, IDH1/IDH2 Are Good Targets for Monitoring Minimal Residual Disease (MRD) in Acute Myeloid Leukemia (AML): A Pilot Study of the ALFA Group. <i>Blood</i> , 2014, 124, 2327-2327.	0.6	1
94	Prognostic Value of Multi-Drug Resistance 1 Gene (MDR1) Expression in Newly Diagnosed Patients with Chronic Myeloid Leukemia on Nilotinib Treatmentâ€”a Subanalysis of the ENEST1st Study. <i>Blood</i> , 2014, 124, 3144-3144.	0.6	1
95	Final Analysis of the ALFA 0701 Study. <i>Blood</i> , 2014, 124, 376-376.	0.6	20
96	Seven-Year (yr) Follow-up of Patients (pts) with Imatinib-Resistant or -Intolerant Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Receiving Dasatinib in Study CA180-034, Final Study Results. <i>Blood</i> , 2014, 124, 520-520.	0.6	3
97	Nilotinib (Tasigna®) and Chemotherapy for First-Line Treatment in Elderly Patients with De Novo Philadelphia Chromosome/BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL): A Trial of the European Working Group for Adult ALL (EWALL-PH-02). <i>Blood</i> , 2014, 124, 798-798.	0.6	31
98	Dasatinib or Nilotinib Discontinuation in Chronic Phase (CP)-Chronic Myeloid Leukemia (CML) Patients (pts) with Durably Undetectable BCR-ABL Transcripts: Interim Analysis of the STOP 2G-TKI Study with a Minimum Follow-up of 12 Months â€” on Behalf of the French CML Group Filmc. <i>Blood</i> , 2014, 124, 811-811.	0.6	17
99	MRD assessed by <i>WT1</i> and <i>NPM1</i> transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin. <i>Oncotarget</i> , 2014, 5, 6280-6288.	0.8	71
100	Tolerability and efficacy of pegylated interferon±2a in combination with imatinib for patients with chronicâ€”phase chronic myeloid leukemia. <i>Cancer</i> , 2013, 119, 4284-4289.	2.0	16
101	Clinical efficacy of second generation tyrosine kinase inhibitor and 5-azacytidine combination in chronic myelogenous leukaemia in myeloid blast crisis. <i>European Journal of Cancer</i> , 2013, 49, 3666-3670.	1.3	18
102	Long-Term Follow-Up of the Imatinib GRAAPH-2003 Study in Newly Diagnosed Patients with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A GRAALL Study. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 150-155.	2.0	140
103	European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. <i>Blood</i> , 2013, 122, 872-884.	0.6	1,743
104	Longâ€”term safety and efficacy of imatinib mesylate (Gleevec®) in elderly patients with chronic phase chronic myelogenous leukemia: Results of the AFR04 study. <i>American Journal of Hematology</i> , 2013, 88, 1-4.	2.0	25
105	Clinical Resistance To Ruxolitinib Is More Frequent In Patients Without MPN-Associated Mutations and Is Rarely Due To Mutations In The JAK2 Kinase Drug-Binding Domain. <i>Blood</i> , 2013, 122, 1591-1591.	0.6	11
106	Long Term Follow-Up After Imatinib Cessation For Patients Indeep Molecular Response: The Update Results Of The STIM1 Study. <i>Blood</i> , 2013, 122, 255-255.	0.6	21
107	Identification Of Patients (pts) With Chronic Myeloid Leukemia (CML) At High Risk Of Artery Occlusive Events (AOE) During Treatment With The 2nd Generation Tyrosine Kinase Inhibitor (TKI) Nilotinib, Using Risk Stratification For Cardiovascular Diseases (CVD). <i>Blood</i> , 2013, 122, 2726-2726.	0.6	8
108	Prediction Of Second Generation Tyrosine Kinase Inhibitors Response After Imatinib Failure: The Value Of The Hammersmith Prediction Score. <i>Blood</i> , 2013, 122, 383-383.	0.6	2

#	ARTICLE	IF	CITATIONS
109	Preliminary Report Of The STIM2 Study: A Multicenter Stop Imatinib Trial For Chronic Phase Chronic Myeloid Leukemia De Novo Patients On Imatinib. <i>Blood</i> , 2013, 122, 654-654.	0.6	41
110	High imatinib dose overcomes insufficient response associated with ABCG2 haplotype in chronic myelogenous leukemia patients. <i>Oncotarget</i> , 2013, 4, 1582-1591.	0.8	26
111	Erosion Of The Chronic Myeloid Leukemia Stem Cell Pool By PPAR γ Agonists. <i>Blood</i> , 2013, 122, 5197-5197.	0.6	0
112	Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. <i>Lancet</i> , The, 2012, 379, 1508-1516.	6.3	839
113	Second attempt to discontinue imatinib in CP-CML patients with a second sustained complete molecular response. <i>Blood</i> , 2012, 120, 1959-1960.	0.6	25
114	Curing Chronic Myeloid Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2012, 7, 103-108.	1.2	24
115	Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet. <i>Blood</i> , 2012, 119, 5963-5971.	0.6	69
116	Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia. <i>Leukemia Research</i> , 2012, 36, 316-323.	0.4	50
117	Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50-70 year old: A phase 1/2 study of the acute leukemia French association. <i>American Journal of Hematology</i> , 2012, 87, 62-65.	2.0	35
118	Two Years Follow-up Results of Graspall/Graall-SA2-2008 Study: L-Asparaginase-Loaded Red Blood Cell Combined with Standard EWALL Chemotherapy in Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (Ph-ALL). <i>Blood</i> , 2012, 120, 1473-1473.	0.6	2
119	Pegylated Interferon- α 2a in Combination to Nilotinib As First Line Therapy in Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia Provides High Rates of MR4.5. Preliminary Results of a Phase II Study.. <i>Blood</i> , 2012, 120, 166-166.	0.6	14
120	Relationship Between Molecular Responses and Disease Progression in Patients (Pts) Treated First Line with Imatinib (Im) Based Regimens: Impact of Treatment Arm within the French Spirit Trial From the French CML Group (FI LMC). <i>Blood</i> , 2012, 120, 168-168.	0.6	4
121	Ruxolitinib Therapy in Myelofibrosis: Analysis of 241 Patients Treated in Compassionate Use (French) Tj ETQq1 1 0.784314 rgBT /Over 2841-2841.	0.6	2
122	Evaluation of Leukemic Stem Cell Persistence in Chronic Myeloid Leukemia (CML) Patients in Complete Molecular Remission Induced by First Line TKI Therapies. <i>Blood</i> , 2012, 120, 3726-3726.	0.6	2
123	Pharmacologic Monitoring of Dasatinib As First Line Therapy in Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CP-CML) Identifies Patients At Higher Risk of Pleural Effusion: A Sub-Analysis of the OPTIM-Dasatinib Trial. <i>Blood</i> , 2012, 120, 3770-3770.	0.6	14
124	Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients \geq 60 Years of Age with FLT3 ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2012, 120, 48-48.	0.6	64
125	Dasatinib (Sprycel $\text{\textcircled{R}}$) and Low Intensity Chemotherapy for First-Line Treatment in Patients with De Novo Philadelphia Positive ALL Aged 55 and Over: Final Results of the EWALL-Ph-01 Study. <i>Blood</i> , 2012, 120, 666-666.	0.6	13
126	Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients with FLT3-ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia After Second-Line Chemotherapy or Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2012, 120, 673-673.	0.6	90

#	ARTICLE	IF	CITATIONS
127	Targeting STAT5 Expression Resulted in Molecular Response Improvement in Patients with Chronic Phase CML Treated with Imatinib. <i>Blood</i> , 2012, 120, 696-696.	0.6	4
128	Discontinuation of Second Generation (2G) Tyrosine Kinase Inhibitors (TKI) in Chronic Phase (CP)-Chronic Myeloid Leukemia (CML) Patients with Stable Undetectable BCR-ABL Transcripts. <i>Blood</i> , 2012, 120, 916-916.	0.6	28
129	ABCG2 Polymorphism Is Associated with Lower Major Molecular Response Rates in CML Patients Treated with 400 Mg Imatinib but Not in Patients Treated with 600 Mg Imatinib.. <i>Blood</i> , 2012, 120, 2465-2465.	0.6	0
130	Minimal Residual Disease Assessed by WT1 Expression and NPM1 Mutations Specific RQ-PCR Assays Identifies Patients with Distinct Outcomes in the ALFA 0701 Trial and Is Decreased by Treatment with Gemtuzumab Ozogamicin. <i>Blood</i> , 2012, 120, 659-659.	0.6	4
131	Optimal Pharmacotherapeutic Management of Acute Lymphoblastic Leukaemia in the Elderly. <i>Drugs and Aging</i> , 2011, 28, 749-764.	1.3	6
132	Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia. <i>Blood</i> , 2011, 118, 6030-6036.	0.6	103
133	Pegylated IFN- \pm 2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone. <i>Leukemia Research</i> , 2011, 35, 80-86.	0.4	16
134	The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFRO1 study). <i>Leukemia Research</i> , 2011, 35, 777-782.	0.4	27
135	A randomized study of pegylated liposomal doxorubicin versus continuous-infusion doxorubicin in elderly patients with acute lymphoblastic leukemia: the GRAALL-SA1 study. <i>Haematologica</i> , 2011, 96, 245-252.	1.7	62
136	A Phase II Open-Label, Ac220 Monotherapy Efficacy Study In Patients with Refractory/Relapsed Flt3-ltd Positive Acute Myeloid Leukemia: Updated Interim Results. <i>Blood</i> , 2011, 118, 2576-2576.	0.6	12
137	Clofarabine Combinations in Adults with Refractory/Relapsed Acute Lymphoblastic Leukemia (ALL): A GRAALL Report. <i>Blood</i> , 2011, 118, 2586-2586.	0.6	4
138	Gemtuzumab Ozogamicin-Based Salvage, Followed by Allogeneic Hematopoietic Stem Cell Transplantation, Is Highly Effective in Young Patients with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) in First Relapse. <i>Blood</i> , 2011, 118, 2603-2603.	0.6	1
139	Complete Hematological, Molecular and Histological Remissions without Cytoreductive Treatment Lasting After Pegylated-Interferon \pm 2a (peg-IFN \pm 2a) Therapy in Polycythemia Vera (PV): Long Term Results of a Phase 2 Trial. <i>Blood</i> , 2011, 118, 280-280.	0.6	8
140	Fluctuating Values of Molecular Residual Disease (MRD) without Molecular Progression After Imatinib Discontinuation in Patients (pts) with Chronic Myeloid Leukemia (CML) Who Have Maintained Complete Molecular Response: Implications for Re-Treatment Criteria and Role of Prior Interferon Therapy. A Pilot Study of the French CML Group (FILMC).. <i>Blood</i> , 2011, 118, 3781-3781.	0.6	3
141	Fractionated Doses of Gemtuzumab Ozogamicin (GO) Combined to Standard Chemotherapy (CT) Improve Event-Free and Overall Survival in Newly-Diagnosed De Novo AML Patients Aged 50-70 Years Old: A Prospective Randomized Phase 3 Trial From the Acute Leukemia French Association (ALFA). <i>Blood</i> , 2011, 118, 6-6.	0.6	14
142	Discontinuation of Imatinib in Patients with Chronic Myeloid Leukemia Who Have Maintained Complete Molecular Response: Update Results of the STIM Study. <i>Blood</i> , 2011, 118, 603-603.	0.6	19
143	Discontinuation of Dasatinib or Nilotinib in Chronic Myeloid Leukemia (CML) Patients (pts) with Stable Undetectable Bcr-Abl Transcripts: Results From the French CML Group (FILMC). <i>Blood</i> , 2011, 118, 604-604.	0.6	11
144	Clonal heterogeneity in acute lymphoblastic leukemias. <i>Hematologie</i> , 2011, 17, 120-122.	0.0	0

#	ARTICLE	IF	CITATIONS
145	Pegylated Interferon a2a (PegIFN) At the Dose of 451¼g Per Week in Combination with Imatinib 400mg Is the Recommended Initial Dose for Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML-CP): Results From the French SPIRIT Trial of the French CML Group (FI LMC). <i>Blood</i> , 2011, 118, 456-456.	0.6	2
146	A Prospective Monocentric Study of Fractionated Gemtuzumab Ozogamicin (GO) Combined to Standard-Dose Cytarabine in Older Patients with Acute Myeloid Leukemia (AML) in First Relapse,. <i>Blood</i> , 2011, 118, 3603-3603.	0.6	31
147	L-Asparaginase-Loaded Red Blood Cells Combined with Standard EWALL Chemotherapy in Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (Ph-) Tj ETQq1 10.784314 rgBT /C		
148	Use of Clofarabine in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia in Adults: The French Experience. <i>Blood</i> , 2011, 118, 2623-2623.	0.6	0
149	Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. <i>Haematologica</i> , 2010, 95, 324-328.	1.7	98
150	Randomized Study of Intensified Anthracycline Doses for Induction and Recombinant Interleukin-2 for Maintenance in Patients With Acute Myeloid Leukemia Age 50 to 70 Years: Results of the ALFA-9801 Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 808-814.	0.8	209
151	Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. <i>Haematologica</i> , 2010, 95, 232-240.	1.7	231
152	Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2010, 363, 2511-2521.	13.9	362
153	Imatinib assay by HPLC with photodiode-array UV detection in plasma from patients with chronic myeloid leukemia: Comparison with LC-MS/MS. <i>Clinica Chimica Acta</i> , 2010, 411, 140-146.	0.5	61
154	Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. <i>Lancet Oncology</i> , The, 2010, 11, 1029-1035.	5.1	1,359
155	Dasatinib Induces a Rapid, Dose-Controllable Mobilization of Cytotoxic Lymphocytes: A Novel Immunomodulatory Effect Associated with Prolonged Therapy Responses In Advanced Leukemia.. <i>Blood</i> , 2010, 116, 1204-1204.	0.6	6
156	Dasatinib (Sprycel®) and Low Intensity Chemotherapy for First-Line Treatment In Elderly Patients with De Novo Philadelphia Positive ALL (EWALL-PH-01): Kinetic of Response, Resistance and Prognostic Significance. <i>Blood</i> , 2010, 116, 172-172.	0.6	15
157	A More Sensitive RQ-PCR to Assess Complete Molecular Remission Does Not Allow the Prediction of Relapse After Discontinuation of Imatinib In Chronic Myeloid Leukemia.. <i>Blood</i> , 2010, 116, 2298-2298.	0.6	5
158	Mutations of TET2, IDH1, IDH2 and ASXL1 In Chronic Myeloid Leukemia.. <i>Blood</i> , 2010, 116, 3377-3377.	0.6	2
159	Pharmacokinetics of Dasatinib as a First Line Therapy In Newly Diagnosed CML Patients (OPTIM dasatinib) Tj ETQq1 10.784314 rgBT /C		
160	Phase I Study to Assess the Safety and Tolerability of AZD1152 In Combination with Low Dose Cytosine Arabinoside In Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2010, 116, 656-656.	0.6	10
161	Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome. <i>Oncotarget</i> , 2010, 1, 34-42.	0.8	115
162	NFκB inhibition triggers death of imatinib-sensitive and imatinib-resistant chronic myeloid leukemia cells including T315I BcrAbl mutants. <i>International Journal of Cancer</i> , 2009, 125, 308-317.	2.3	40

#	ARTICLE	IF	CITATIONS
163	When can real-time quantitative RT-PCR effectively define molecular relapse in acute promyelocytic leukemia patients? (Results of the French Belgian Swiss APL Group). <i>Leukemia Research</i> , 2009, 33, 1178-1182.	0.4	14
164	Azacitidine in Refractory or Relapsed AML After Intensive Chemotherapy (IC): Results of the French ATU Program.. <i>Blood</i> , 2009, 114, 1054-1054.	0.6	5
165	Phase I/II Study to Assess the Safety and Efficacy of the Aurora B Kinase Inhibitor, AZD1152, in Patients with Advanced Acute Myeloid Leukemia.. <i>Blood</i> , 2009, 114, 2080-2080.	0.6	5
166	Long-Term Results of the Imatinib GRAAPH-2003 Study in Newly-Diagnosed Patients with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia... <i>Blood</i> , 2009, 114, 3080-3080.	0.6	7
167	Discontinuation of Imatinib Therapy After Achieving a Molecular Response in Chronic Myeloid Leukemia Patients.. <i>Blood</i> , 2009, 114, 859-859.	0.6	24
168	Quantification of VEGF isoforms and VEGFR transcripts by qRT-PCR and their significance in acute myeloid leukemia. <i>International Journal of Biological Markers</i> , 2009, 24, 22-31.	0.7	11
169	Front-Line Imatinib Mesylate (IM) in Patients with Newly Diagnosed Accelerated Phase (AP)-Chronic Myeloid Leukemia (CML), a Study From the FILMC Group (France Intergroupe Leucemie Myeloide) Tj ETQq1 1 0.784314 rgBT/Overlo	0.6	4
170	Hodgkin Variant of Richter's Syndrome: Report of 34 Cases. A Role of EBV in Transformation.. <i>Blood</i> , 2009, 114, 1550-1550.	0.6	0
171	Treatment of Lower Risk MDS with Del 5q with Lenalidomide (LEN): Results of the French ATU Program.. <i>Blood</i> , 2009, 114, 2764-2764.	0.6	20
172	Molecular Response, Efficacy and Safety Analysis of 168 Adult French Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) From the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.. <i>Blood</i> , 2009, 114, 3293-3293.	0.6	1
173	Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. <i>Nature Medicine</i> , 2008, 14, 1333-1342.	15.2	325
174	Dasatinib-Associated Major Molecular Responses Are Rapidly Achieved in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Following Resistance, Suboptimal Response, or Intolerance on Imatinib.. <i>Blood</i> , 2008, 112, 1095-1095.	0.6	9
175	Randomized Comparison of Imatinib Versus Imatinib Combination Therapies in Newly Diagnosed Chronic Myeloid Leukaemia (CML) Patients in Chronic Phase (CP): First Results of the Phase III (SPIRIT) Trial from the French CML Group (FI LMC). <i>Blood</i> , 2008, 112, 183-183.	0.6	12
176	Is It Possible to Stop Imatinib in Patients with Chronic Myeloid Leukemia? An Update from a French Pilot Study and First Results from the Multicentre "Stop Imatinib" (STIM) Study. <i>Blood</i> , 2008, 112, 187-187.	0.6	13
177	Dasatinib (Sprycel®) and Chemotherapy for First-Line Treatment in Elderly Patients with De Novo Philadelphia Positive ALL: Results of the First 22 Patients Included in the EWALL-Ph-01 Trial (on Behalf) Tj ETQq1 1 0.784314 rgBT/Overlo	0.6	14
178	First European Chemotherapy Schedule for Elderly Patients with Acute Lymphoblastic Leukemia: Promising Remission Rate and Feasible Moderate Dose Intensity Consolidation. <i>Blood</i> , 2008, 112, 304-304.	0.6	15
179	Dasatinib Dose-Optimization in Chronic Phase Chronic Myeloid Leukemia (CML-CP): Two-Year Data from CA180-034 Show Equivalent Long-Term Efficacy and Improved Safety with 100 Mg Once Daily Dose. <i>Blood</i> , 2008, 112, 3225-3225.	0.6	17
180	Epigenetic Therapy with 5-Azacitidine, Valproic Acid, and ATRA in Patients with High-Risk AML or MDS: Results of the French VIVEDEP Phase II Study. <i>Blood</i> , 2008, 112, 763-763.	0.6	10

#	ARTICLE	IF	CITATIONS
181	Cognitive Study of Reactivity to IPH1101 of Peripheral T Lymphocytes from Chronic Myeloid Leukemia, Multiple Myeloma and Follicular Lymphoma Patients.. Blood, 2008, 112, 1530-1530.	0.6	3
182	A Randomised Phase II Study of Pegylated Liposomal Doxorubicine in Elderly Patients with Acute Lymphoblastic Leukemia (ALL): The GRAALL-SA1 Study.. Blood, 2008, 112, 918-918.	0.6	6
183	Lung Abnormalities after Dasatinib Treatment for Chronic Myeloid Leukemia. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 814-818.	2.5	189
184	Durable responses to imatinib in patients with PDGFRB fusion geneâ€“positive and BCR-ABLâ€“negative chronic myeloproliferative disorders. Blood, 2007, 109, 61-64.	0.6	156
185	Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood, 2007, 109, 58-60.	0.6	505
186	Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosomeâ€“positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood, 2007, 109, 1408-1413.	0.6	300
187	Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood, 2007, 109, 5143-5150.	0.6	356
188	Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood, 2007, 109, 3207-3213.	0.6	400
189	Randomized Comparison of Standard Induction with Daunorubicin (DNR) for 3 Days vs Idarubicin (IDA) for 3 or 4 Days in AML pts Aged 50 to 70 and of Maintenance with Interleukin 2. Final Analysis of the ALFA 9801 Study.. Blood, 2007, 110, 162-162.	0.6	16
190	Maintenance Therapy by Glivec® and Pegasys® in Patients with Philadelphia Positive Acute Lymphocytic Leukemia Not Eligible for Hematopoietic Stem Cell Transplantation.. Blood, 2007, 110, 2812-2812.	0.6	3
191	Prognostic Significance of CD20 Expression in Adult B-Cell Precursor Acute Lymphoblastic Leukemia.. Blood, 2007, 110, 2829-2829.	0.6	2
192	Dasatinib or High-Dose Imatinib for Patients with Chronic-Phase Chronic Myeloid Leukemia Resistant to Standard-Dose Imatinib: 2-Year Follow-Up Data from START-R (CA180-017).. Blood, 2007, 110, 736-736.	0.6	7
193	High Efficacy and Particular Safety Profile of Imatinib Mesylate (Glivec®) in Elderly Patients with CML in Chronic Phase: Results of the AFR04 Prospective Study.. Blood, 2007, 110, 1039-1039.	0.6	0
194	Outcome of Patients with T-Cell Lymphoblastic Leukemia or Lymphoma: The GRAALL Experience.. Blood, 2007, 110, 2818-2818.	0.6	0
195	Results of the AFR07 Prospective Study in De Novo Philadelphia Positive ALL Patients Aged over 55 Years: Efficacy and Safety of a Glivec® Based Induction Followed by Maintenance Therapy with Glivec® and Pegasys®.. Blood, 2007, 110, 2816-2816.	0.6	0
196	Occurrence and Kinetics of False-Positive Aspergillus Galactomannan Test Results following Treatment with Lactam Antibiotics in Patients with Hematological Disorders. Journal of Clinical Microbiology, 2006, 44, 389-394.	1.8	150
197	Diagnostics, Prognostic and Therapeutic Exploitation of Telomeres and Telomerase in Leukemias. Current Pharmaceutical Biotechnology, 2006, 7, 171-183.	0.9	10
198	BCR/ABL Oncogene Directly Controls MHC Class I Chain-Related Molecule A Expression in Chronic Myelogenous Leukemia. Journal of Immunology, 2006, 176, 5108-5116.	0.4	126

#	ARTICLE	IF	CITATIONS
199	Imatinib mesylate minimally affects bcr-abl+ and normal monocyte-derived dendritic cells but strongly inhibits T cell expansion despite reciprocal dendritic cell-T cell activation. <i>Journal of Leukocyte Biology</i> , 2006, 79, 747-756.	1.5	19
200	Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2006, 355, 2408-2417.	13.9	3,212
201	The role of the K247R substitution in the ABL tyrosine kinase domain in sensitivity to imatinib. <i>Haematologica</i> , 2006, 91, 137-8.	1.7	7
202	Farnesyltransferase inhibitor tipifarnib (R115777) preferentially inhibits in vitro autonomous erythropoiesis of polycythemia vera patient cells. <i>Blood</i> , 2005, 105, 3743-3745.	0.6	5
203	A non-randomised dose-escalating phase II study of thalidomide for the treatment of patients with low-risk myelodysplastic syndromes: the Thal-SMD-2000 trial of the Groupe Francais des Myelodysplasies. <i>British Journal of Haematology</i> , 2005, 131, 609-618.	1.2	44
204	Randomized Comparison of Imatinib with Imatinib Combination Therapies in Newly Diagnosed Chronic Myelogenous Leukemia Patients in Chronic Phase: Design and First Interim Analysis of a Phase III Trial from the French CML Group.. <i>Blood</i> , 2005, 106, 168-168.	0.6	5
205	Bone marrow histological patterns can predict survival of patients with grade 1 or 2 follicular lymphoma: a study from the Groupe d'Etude des Lymphomes Folliculaires. <i>British Journal of Haematology</i> , 2004, 126, 364-371.	1.2	27
206	Arsenic trioxide is effective in the treatment of multiple myeloma in SCID mice. <i>European Journal of Haematology</i> , 2004, 72, 166-171.	1.1	37
207	A Phase I/II Dose Escalating Study of Daunorubicin Combined with Imatinib Mesylate and Cytarabine as Induction Therapy for Chronic Myelogenous Leukaemia in Myeloid Blast Crisis. Preliminary Results of the AFR01 Trial.. <i>Blood</i> , 2004, 104, 1002-1002.	0.6	1
208	Vascular Endothelial Growth Factor 121 (VEGF121) Isoform mRNA Is Predictive of Poor Prognosis in Acute Myeloid Leukemia (AML) .. <i>Blood</i> , 2004, 104, 2007-2007.	0.6	0
209	Relationship between elevated levels of the alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec®) in vitro and in vivo. <i>Biochemical Pharmacology</i> , 2003, 66, 1907-1913.	2.0	60
210	Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate. <i>British Journal of Haematology</i> , 2003, 120, 1091-1092.	1.2	35
211	PML-RARA targeted DNA vaccine induces protective immunity in a mouse model of leukemia. <i>Nature Medicine</i> , 2003, 9, 1413-1417.	15.2	72
212	Combined Treatment With Arsenic Trioxide and All-Trans-Retinoic Acid in Patients With Relapsed Acute Promyelocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2003, 21, 2326-2334.	0.8	146
213	Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2003, 348, 994-1004.	13.9	3,227
214	Should Adolescents With Acute Lymphoblastic Leukemia Be Treated as Old Children or Young Adults? Comparison of the French FRALLE-93 and LALA-94 Trials. <i>Journal of Clinical Oncology</i> , 2003, 21, 774-780.	0.8	552
215	Acute Monocytic Leukemia Presenting as Acute Respiratory Failure. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2003, 167, 1329-1333.	2.5	120
216	CD11c gene expression in hairy cell leukemia is dependent upon activation of the proto-oncogenes ras and junD. <i>Blood</i> , 2003, 101, 4033-4041.	0.6	41

#	ARTICLE	IF	CITATIONS
217	Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase. <i>Blood</i> , 2003, 102, 4298-4305.	0.6	59
218	Fertility in young women after chemotherapy with alkylating agents for Hodgkin and non-Hodgkin lymphomas. <i>The Hematology Journal</i> , 2003, 4, 116-120.	2.0	57
219	Imatinib in combination with cytarabine for the treatment of Philadelphia-positive chronic myelogenous leukemia chronic-phase patients: Rationale and design of phase I/II trials. <i>Seminars in Hematology</i> , 2003, 40, 92-97.	1.8	1
220	In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2002, 117, 860-868.	1.2	144
221	Potential mechanisms of resistance to cytarabine in AML patients. <i>Leukemia Research</i> , 2002, 26, 621-629.	0.4	125
222	Expression of high Km 5'-nucleotidase in leukemic blasts is an independent prognostic factor in adults with acute myeloid leukemia. <i>Blood</i> , 2001, 98, 1922-1926.	0.6	80
223	Primary plasma cell leukaemia: a report of 18 cases. <i>Leukemia Research</i> , 2001, 25, 103-107.	0.4	78
224	Functional G-CSF pathways in t(8;21) leukemic cells allow for differentiation induction and degradation of AML1-ETO. <i>The Hematology Journal</i> , 2000, 1, 316-328.	2.0	17
225	Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2000, 111, 196-203.	1.2	138
226	Minimally differentiated erythroleukaemia (AML M6 Variant ¹): a rare subset of AML distinct from AML M6. <i>British Journal of Haematology</i> , 1995, 90, 868-875.	1.2	62
227	Unusual specific cutaneous lesions in myelodysplastic syndromes. <i>Journal of the American Academy of Dermatology</i> , 1995, 33, 187-191.	0.6	50